» Articles » PMID: 37971296

Synthesis of Peptide-siRNA Conjugates Via Internal Sulfonylphosphoramidate Modifications and Evaluation of Their in Vitro Activity

Overview
Specialty Biochemistry
Date 2023 Nov 16
PMID 37971296
Authors
Affiliations
Soon will be listed here.
Abstract

Conjugates of therapeutic oligonucleotides (ONs) including peptide conjugates, provide a potential solution to the major challenge of specific tissue delivery faced by this class of drugs. Conjugations are often positioned terminal at the ONs, although internal placement of other chemical modifications are known to be of critical importance. The introduction of internal conjugation handles in chemically modified ONs require highly specialized and expensive nucleoside phosphoramidites. Here, we present a method for synthesizing a library of peptide-siRNA conjugates by conjugation at internal phosphorous positions via sulfonylphosphoramidate modifications incorporated into the sense strand. The sulfonylphosphoramidate modification offers benefits as it can be directly incorporated into chemically modified ONs by simply changing the oxidation step during synthesis, and furthermore holds the potential to create multifunctionalized therapeutic ONs. We have developed a workflow using a novel pH-controlled amine-to-amine linker that yields peptide-siRNA conjugates linked via amide bonds, and we have synthesized conjugates between GLP1 peptides and a HPRT1 siRNA as a model system. The in vitro activity of the conjugates was tested by GLP1R activity and knockdown of the HPRT1 gene. We found that conjugation near the 3'-end is more favorable than certain central internal positions and different internal conjugation strategies were compared.

Citing Articles

Peptide-Oligonucleotide Conjugation: Chemistry and Therapeutic Applications.

Malinowska A, Huynh H, Bose S Curr Issues Mol Biol. 2024; 46(10):11031-11047.

PMID: 39451535 PMC: 11506717. DOI: 10.3390/cimb46100655.


LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo.

Broc B, Varini K, Sonnette R, Pecqueux B, Benoist F, Masse M Pharmaceutics. 2024; 16(4).

PMID: 38675209 PMC: 11054735. DOI: 10.3390/pharmaceutics16040548.


Cholesterol Conjugates of Small Interfering RNA: Linkers and Patterns of Modification.

Chernikov I, Ponomareva U, Meschaninova M, Bachkova I, Vlassov V, Zenkova M Molecules. 2024; 29(4).

PMID: 38398538 PMC: 10892548. DOI: 10.3390/molecules29040786.


A Convenient Oligonucleotide Conjugation via Tandem Staudinger Reaction and Amide Bond Formation at the Internucleotidic Phosphate Position.

Klabenkova K, Zhdanova P, Burakova E, Bizyaev S, Fokina A, Stetsenko D Int J Mol Sci. 2024; 25(4).

PMID: 38396686 PMC: 10889076. DOI: 10.3390/ijms25042007.

References
1.
Winkler J . Oligonucleotide conjugates for therapeutic applications. Ther Deliv. 2013; 4(7):791-809. PMC: 3787477. DOI: 10.4155/tde.13.47. View

2.
Sugo T, Terada M, Oikawa T, Miyata K, Nishimura S, Kenjo E . Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J Control Release. 2016; 237:1-13. DOI: 10.1016/j.jconrel.2016.06.036. View

3.
Nikan M, Tanowitz M, Dwyer C, Jackson M, Gaus H, Swayze E . Targeted Delivery of Antisense Oligonucleotides Using Neurotensin Peptides. J Med Chem. 2020; 63(15):8471-8484. DOI: 10.1021/acs.jmedchem.0c00840. View

4.
Ostergaard M, Jackson M, Low A, Chappell A, Lee R, Peralta R . Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates. Nucleic Acids Res. 2019; 47(12):6045-6058. PMC: 6614849. DOI: 10.1093/nar/gkz360. View

5.
Astakhova I, Hansen L, Vester B, Wengel J . Peptide-LNA oligonucleotide conjugates. Org Biomol Chem. 2013; 11(25):4240-9. DOI: 10.1039/c3ob40786a. View